Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 6/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477035 | 0.83 | KDM1A (0.46) | TLR9TLR8TLR7DRD2SLC18A3 | |
| SCHEMBL17308223 | 0.83 | TLR9 (0.46) | TLR9TLR8TLR7DRD2SLC18A3 | |
| SCHEMBL14923996 | 0.81 | DRD2 (0.54) | TLR9TLR8TLR7DRD2HPGD | |
| SCHEMBL17320468 | 0.80 | DRD2 (0.46) | TLR9TLR8TLR7DRD2SLC18A3 | |
| SCHEMBL20004333 | 0.80 | DRD2 (0.54) | DRD2HPGDSLC18A3PRCP | |
| SCHEMBL17306126 | 0.80 | SLC18A3 (0.49) | TLR9TLR8TLR7DRD2HPGD | |
| SCHEMBL15168408 | 0.80 | SLC18A3 (0.47) | TLR9TLR8TLR7DRD2SLC18A3 | |
| SCHEMBL25042445 | 0.79 | SLC18A3 (0.49) | TLR9TLR8TLR7DRD2SLC18A3 | |
| SCHEMBL22537840 | 0.78 | DRD2 (0.51) | DRD2PRCP | |
| SCHEMBL25240806 | 0.77 | MEN1 (0.44) | TLR9TLR8TLR7DRD2SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | TLR9 3502/4885TLR8 3481/4885TLR7 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.